Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00970229 · ClinicalTrials.gov registry record · Phase 1
Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.
A Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00970229 is a Phase 1 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 19 participants.
The verdict
NCT00970229, a Phase 1 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The underlying goal of this study is to assess \[123I\]MNI-420 SPECT imaging as a tool to detect A2aR density in the brain of PD and HD research participants to be compared with similarly aged healthy subjects.
Interventions
- DRUG [123I]MNI-420
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2009-07 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00970229
The ClinicalTrials.gov registry entry for NCT00970229 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [123I]MNI-420 is the first listed.
NCT00970229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00970229 about?
NCT00970229 is a clinical study titled "Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.". The underlying goal of this study is to assess \[123I\]MNI-420 SPECT imaging as a tool to detect A2aR density in the brain of PD and HD research participants to be compared with similarly aged healthy subjects.
What is the current status of trial NCT00970229?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2009-07. Estimated completion is 2015-05.
What interventions are being tested in trial NCT00970229?
The interventions under investigation include: [123I]MNI-420 (DRUG).
Who is sponsoring clinical trial NCT00970229?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.